Last Updated on January 6, 2024 by The Health Master
Zydus Lifesciences on Thursday said it has received three observations from USFDA following inspection of its Jarod (Vadodara) based manufacturing facility.
The US drug regulator inspected the injectable facility from February 24 to March 10, 2022.
The inspection closed with three observations, the drug firm said in a regulatory filing.
“We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network,” Zydus Lifesciences said.
USFDA issues its observations through Form 483 at the conclusion of an inspection if the investigators have observed any conditions that may violate current good manufacturing practices.
Draft of Medical Devices Amendment Rule 2022: Pharmacy academic community raises…
WHO issues new guidelines on Abortion
USFDA gives nod to Strides Pharma for Colchicine tablets
NITI Aayog to release policy on integrative medicine, white paper onmanufacturing Medical Devices
DCGI gives EUA nod to Covovax for 12-17 years age group
Govt joins hands with industry to set up Pharma Park
Mandatory QR codes on APIs: Benefit or burden?
USFDA gives nod to Alembic Pharmaceuticals for anti fungal drug
Govt amends rules to allow import license for Medical Devices: Read
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
